Informace o publikaci

Lower-Limb Lymphedema after Sentinel Lymph Node Biopsy in Cervical Cancer Patients

Autoři	CIBULA David BORCINOVA Martina MARNITZ Simone JARKOVSKÝ Jiří KLAT Jaroslav PILKA Radovan TORNE Aureli ZAPARDIEL Ignacio PETIZ Almerinda LAY Laura SEHNAL Borek PONCE Jordi FELSINGER Michal ARENCIBIA-SANCHEZ Octavio KASCAK Peter ZALEWSKI Kamil PRESL Jiri PALOP-MOSCARDO Alicia TINGULSTAD Solveig VERGOTE Ignace REDECHA Mikulas FRUHAUF Filip KOHLER Christhardt KOCIAN Roman
Rok publikování	2021
Druh	Článek v odborném periodiku
Časopis / Zdroj	Cancers
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
www	https://www.mdpi.com/2072-6694/13/10/2360
Doi	http://dx.doi.org/10.3390/cancers13102360
Klíčová slova	cervical cancer; sentinel lymph node biopsy; lower limb lymphedema; pelvic lymphadenectomy
Popis	Simple Summary Lower-limb lymphedema (LLL) is a well-recognized adverse outcome of the surgical management of cervical cancer. Recently, sentinel lymph node (SLN) biopsy has emerged as an alternative procedure to systematic pelvic lymphadenectomy (PLND) aiming to decrease the risk of complications, especially LLL development. Our study represents the first prospective analysis of LLL incidence in cervical cancer patients after a uterine procedure with SLN biopsy, without systematic PLND. In an international multicenter trial SENTIX, the group of 150 patients was prospectively evaluated using both objective and subjective LLL assessments in 6 months intervals for 2 years. Contrary to the expectations, our results showed that SLN biopsy does not eliminate the risk of LLL development which occurred in a mild or moderate stage in about 26% of patients with a median interval to the onset of 9 months. Background: To prospectively assess LLL incidence among cervical cancer patients treated by uterine surgery complemented by SLN biopsy, without PLND. Methods: A prospective study in 150 patients with stage IA1-IB2 cervical cancer treated by uterine surgery with bilateral SLN biopsy. Objective LLL assessments, based on limb volume increase (LVI) between pre- and postoperative measurements, and subjective patient-perceived swelling were conducted in six-month periods over 24-months post-surgery. Results: The cumulative incidence of LLL at 24 months was 17.3% for mild LLL (LVI 10-19%), 9.2% for moderate LLL (LVI 20-39%), while only one patient (0.7%) developed severe LLL (LVI > 40%). The median interval to LLL onset was nine months. Transient edema resolving without intervention within six months was reported in an additional 22% of patients. Subjective LLL was reported by 10.7% of patients, though only a weak and partial correlation between subjective-report and objective-LVI was found. No risk factor directly related to LLL development was identified. Conclusions: The replacement of standard PLND by bilateral SLN biopsy in the surgical treatment of cervical cancer does not eliminate the risk of mild to moderate LLL, which develops irrespective of the number of SLN removed.